Harton files Form D for $18.1 million private offering
Melrose, Massachusetts biotech Harton, Inc. reported raising $15.1 million of an $18.1 million equity offering from five investors, per an SEC filing dated August 14, 2026.
Harton, Inc., a Delaware corporation based in Melrose, Massachusetts, filed a Form D notice with the SEC disclosing an exempt securities offering. The filing lists a date of first sale of July 30, 2026, and is marked as a new notice rather than an amendment.1
According to the filing, the total offering amount is $18,099,998, with $15,099,998 already sold and $3,000,000 remaining to be sold.1 The company reported five investors have already participated in the offering.1
The offering is being conducted under Rule 506(b) of Regulation D.1 The securities being offered are classified as equity.1 The minimum investment accepted from any outside investor is listed as $0.1
Harton reported no sales commissions or finders' fees associated with the offering1 and no proceeds directed toward payments to executive officers, directors, or promoters.1
The filing identifies Harton's industry as biotechnology within the health care sector.1 The company selected "decline to disclose" for its revenue range and aggregate net asset value range.1
Related persons named in the filing include Richard Terry as an executive officer and director, along with Min Cui, Evan Daugharthy, and Victor Tong as directors, all listed at the company's Melrose address.1
The company indicated it does not intend the offering to last more than one year.1 The filing states the offering is not being made in connection with a business combination transaction such as a merger or acquisition.1
The notice was signed by Richard Terry, Chief Financial Officer, on August 14, 2026.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.